Healthcare products company West Pharmaceutical Services (NYSE:WST) will be reporting earnings this Thursday before market hours. Here’s what to look for.
West Pharmaceutical Services beat analysts’ revenue expectations by 2.1% last quarter, reporting revenues of $804.6 million, up 7.7% year on year. It was a very strong quarter for the company, with a solid beat of analysts’ full-year EPS guidance estimates and a beat of analysts’ EPS estimates.
Is West Pharmaceutical Services a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.
This quarter, analysts are expecting West Pharmaceutical Services’s revenue to grow 6% year on year to $793.4 million, improving from the 2.3% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.83 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. West Pharmaceutical Services has missed Wall Street’s revenue estimates twice over the last two years.
Looking at West Pharmaceutical Services’s peers in the drug development inputs & services segment, some have already reported their Q4 results, giving us a hint as to what we can expect. Medpace delivered year-on-year revenue growth of 32%, beating analysts’ expectations by 3.3%, and IQVIA reported revenues up 10.3%, topping estimates by 2.9%. Medpace traded down 16.1% following the results while IQVIA was also down 7.4%.
Read our full analysis of Medpace’s results here and IQVIA’s results here.
Debates around the economy’s health and the impact of potential tariffs and corporate tax cuts have caused much uncertainty in 2025. While some of the drug development inputs & services stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.7% on average over the last month. West Pharmaceutical Services is down 10.8% during the same time and is heading into earnings with an average analyst price target of $333.57 (compared to the current share price of $243.58).
When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we’ve found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback.